Mediwatch secures five year global distribution agreement with Inverness Medical Innovations
Mediwatch plc has signed a five-year agreement for the worldwide distribution of PSAwatch, its flagship point-of-care total PSA measuring system for prostate cancer, with Inverness Medical Innovations, Inc. According to the company, Inverness has an extensive global sales-force which will complement Mediwatch’s own worldwide distribution network and provide the Company with considerably more market reach.
Philip Stimpson, Mediwatch Chief Executive commented: “We are confident that this strategically important distribution agreement will deliver a significant revenue stream. The market for point of care diagnostics is growing rapidly as a result of a combination of; the population aging, growth of local clinics, home testing and the need for faster, cheaper, more portable and easier to use medical equipment. "
Other news from the department business & finance
